Advice from the MHRA:
Nephrogenic Systemic Fibrosis (NSF) is a debilitating and sometimes fatal condition. It has been associated with some intravenous gadolinium-containing magnetic resonance imaging (MRI) contrast agents in patients with severe renal impairment. On the basis of the available evidence, the UK Commission on Human Medicines (CHM) together with the European Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for Human Use (CHMP) recommended:
- Do not use Omniscan (gadodiamide) in patients with severe renal impairment (ie, GFR [glomerular filtration rate] <30ml/min/1·73m2)>
- Careful consideration should be given to the use of other gadolinium-containing MRI contrast agents in patients with severe renal impairment (ie, GFR <30ml/min/1·73m2).
MHRA Safety Warning
Online GFR calculator
European Society of Urogenital Radiology
RSNA News Feb '07
The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR)
Recent articles in Radiology here and here.